Mary Stuart
The past couple of years have witnessed the formation of more than a dozen companies focused on taking a portfolio...
The past couple of years have witnessed the formation of more than a dozen companies focused on taking a portfolio of very early stage medical devices to the next level. With good ideas and connections, device industry executives, as an alternative to joining operating companies are increasingly joining incubators where they can keep their hands in device company creation over a number of projects. Whether you call these companies incubators or accelerators, they all share the goal of filling a gap between technology and company creation, and funding. Accelerators can help early stage concepts get the hearing they normally might not get either in the venture capital community, which is prepared to take on clinical and market risk but not technological risk, or large companies, which are focused on maintaining existing businesses. In fact, for certain kinds of broadly-enabling platform technologies that cut across clinical specialties, the incubator/accelerator model makes a lot of sense.
Mary Stuart
The past couple of years have witnessed the formation of more than a dozen companies focused on taking a portfolio...
Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.
Comes Days After PDUFA Pushback For GSK's Blenrep.
Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.
Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.
After “intense negotiations”, Bavarian Nordic’s board plans to recommend a DKK19bn ($2.98bn) offer by private equity firms Nordic Capital and Permira to take the company private.
Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.
Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.